WavelinQ™ arteriovenöser endovaskulärer Shunt: eine globale, multizentrische Untersuchung nach Markteinführung (WAVE Global)

Device: WavelinQ™ EndoAVF System

Inclusion Criteria:

The participant must:

1. Be able to comprehend, voluntarily sign and date the informed consent form (ICF) prior
to collection of clinical investigation data or performance of clinical investigation
procedures (or where allowable the participant's legally authorized representative
(LAR) on behalf of the participant).

2. Be able to and willing to comply with the CIP requirements, including clinical
follow-up.

3. Be male or non-pregnant female = 18 years of age with an expected lifespan sufficient
(= 24 months) to allow for completion of all clinical investigation procedures.

4. Have established, non-reversible kidney failure, who are currently on HD at screening
or are in need of a vascular access for HD as determined by the referring clinician.

5. Target treatment vein diameter(s) for AVF creation = 2.0 mm as measured via DUS or
angiography.

6. A target treatment artery diameter = 2.0 mm as measured via DUS or angiography.

7. Adequate collateral circulation to the hand, in the opinion of the Principal
Investigator (PI) (or authorized designee).

8. At least one superficial outflow vein diameter = 2.5 mm as measured via DUS or
angiography that is in communication with the target creation site via a proximal
forearm perforating vein.

Exclusion Criteria:

The participant must not have:

1. Active or nontreated hypercoagulable state.

2. Known bleeding diathesis.

3. Insufficient cardiac output to support the maturation and use of an AVF in the opinion
of the PI (or authorized designee).

4. Known history of or current active intravenous drug abuse.

5. A planned major surgical procedure within 6 months following index procedure or
major surgery, in the opinion of the PI (or authorized designee), within 30 days prior
to index procedure.

6. Known allergy or hypersensitivity to contrast media which cannot be adequately treated
with pre-medication.

7. Known adverse effects to sedation and / or anesthesia which cannot be adequately
treated with pre-medication.

8. Evidence of active infection on the day of the index procedure (temperature of = 38.0°
Celsius and / or White Blood Cell (WBC) Count of = 12,000 cells / µL, if collected).

9. Another medical condition, which, in the opinion of the PI (or authorized designee),
may cause him / her to be non-compliant with the CIP, confound the data
interpretation, or is associated with a life expectancy insufficient to allow for the
completion of clinical investigation procedures and follow-up.

10. Current participation in an investigational drug or device clinical investigation that
has not completed the clinical investigation treatment or that clinically interferes
with the clinical investigation endpoints. Note: Investigations requiring extended
follow-up visits for products that were investigational, but have since become
commercially available, are not considered investigational.

11. Central venous stenosis or central vein narrowing = 50% based on imaging, or any
degree of central venous stenosis with accompanying signs or symptoms, on the same
side as the planned AVF creation.

12. The absence of a proximal forearm perforating vein feeding the target cannulation
vein(s) from the target creation site via DUS or angiography.

13. Occlusion or stenosis = 50%, or any degree of stenosis with accompanying signs or
symptoms of target cannulation vein(s) such as cephalic, median cubital, basilic, etc.
assessed via DUS or angiography and as clinically determined by PI (or authorized
designee).

14. Significantly compromised venous or arterial architecture (e.g. severe vessel
calcification) or flow in the treatment arm as determined by the PI (or authorized
designee) and DUS or angiography.

15. Presence of significant calcification at the target endoAVF location that could
potentially impact the effectiveness of endoAVF creation as determined by the PI (or
authorized designee).